Last reviewed · How we verify

Levodopa dispersible — Competitive Intelligence Brief

Levodopa dispersible (Levodopa dispersible) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor / Antiparkinson agent. Area: Neurology.

marketed Dopamine precursor / Antiparkinson agent Dopamine (via conversion by aromatic amino acid decarboxylase) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Levodopa dispersible (Levodopa dispersible) — Seoul National University Hospital. Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levodopa dispersible TARGET Levodopa dispersible Seoul National University Hospital marketed Dopamine precursor / Antiparkinson agent Dopamine (via conversion by aromatic amino acid decarboxylase)
placebo/L-dopa placebo/L-dopa GlaxoSmithKline marketed Dopamine precursor / Antiparkinson agent Dopamine (via conversion by aromatic amino acid decarboxylase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor / Antiparkinson agent class)

  1. GlaxoSmithKline · 1 drug in this class
  2. Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levodopa dispersible — Competitive Intelligence Brief. https://druglandscape.com/ci/levodopa-dispersible. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: